Reach Us +441234923305


Diego Albrecht | OMICS International
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Diego Albrecht

Translational Medicine, Novartis Institutes for BioMedical Research (NIBR), Basel, Switzerland


Diego Albrecht completed his masters at Cardiff university and currently working as Expert Clinical Manager at Novartis Institutes for Biomedical Research, Switzerland. He has co-authored many scientific papers in leading scientific journals and he has written a number of book chapters.

Assessment of Drug Interaction Potential between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Digoxin or Warfa rin

LCZ696 (sacubitril/valsartan) is a first-in-class angiotensin receptor neprilysin inhibitor that simultaneously inhibits neprilysin and blocks the angiotensin II receptor. LCZ696 has been recently approved for treatment of HF and likely be co-administered with digoxin or warfarin. The drug interaction potential between LCZ696 and digoxin or warfari... Read More»

Surya Ayalasomayajula, Pierre Jordaan, Parasar Pal, Priyamvada Chandra, Diego Albrecht, Thomas Langenickel, Iris Rajman and Gangadhar Sunkara

Research Article: Clin Pharmacol Biopharm 2015, 4:147

DOI: 10.4172/2167-065X.1000147

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF